A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
Clinical trial NCT02392624 · COMPLETED
Trial details
- NCT number
- NCT02392624
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-18
- Primary completion
- 2017-03-09
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.